Biological Therapy in Treating Women With Stage IV Breast Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00027807 |
Recruitment Status :
Completed
First Posted : January 27, 2003
Last Update Posted : February 17, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining different types of biological therapies may kill more tumor cells.
PURPOSE: Phase I/II trial to study the effectiveness of combining different biological therapies in treating women who have stage IV breast cancer.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Breast Cancer | Biological: Aldesleukin Biological: Sargramostim Biological: therapeutic autologous lymphocytes | Phase 1 |
OBJECTIVES:
- Determine the maximum tolerated dose of armed activated T cells given in combination with interleukin-2 and sargramostim (GM-CSF) in women with stage IV breast cancer.
- Determine the toxicity profile of this regimen in these patients.
- Determine the clinical response and overall and progression-free survival of patients treated with this regimen.
OUTLINE: This is a dose-escalation study of armed activated T cells.
Patients undergo peripheral blood mononuclear cell (PBMC) collection. The PBMCs are treated ex vivo with monoclonal antibody OKT3 to form armed activated T cells (ATC). The armed ATC are expanded for 14 days in interleukin-2 (IL-2).
Patients receive armed ATC IV over 30 minutes twice weekly for 4 weeks. Patients also receive IL-2 subcutaneously (SC) once daily and sargramostim (GM-CSF) SC twice weekly beginning 3 days before the first infusion of armed ATC and continuing until 7 days after the last infusion of armed ATC.
Cohorts of 3-6 patients receive escalating doses of armed ATC until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, additional patients are treated at that dose.
Patients are followed at 1, 2, and 5 months and then every 6 months thereafter.
PROJECTED ACCRUAL: A total of 15-30 patients will be accrued for the phase I portion of this study and a total of 18-33 patients will be accrued for the phase II portion of this study within 4-6 years.
PLEASE NOTE: THIS STUDY WAS INTENDED TO BE A PHASE I/II STUDY, BUT NEVER MOVED FORWARD TO PHASE II. (4-22-09)
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 6 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Treatment of Stage IV Breast Cancer With OKT3 x Herceptin Armed Activated T Cells, Low Dose IL-2, And GM-CSF (Phase I Only as of 4-22-09 as Per IRB Approval Date) |
Study Start Date : | October 2001 |
Actual Primary Completion Date : | September 2010 |
Actual Study Completion Date : | March 2013 |

Arm | Intervention/treatment |
---|---|
Experimental: Aldesleukin, Sargramostim & therapeutic autologous lymphocytes
Peripheral blood mononuclear cells (PBMC) for the generation of ATC will be collected using 1 or 2 phereses to obtain 8-20 × 109 PBMC for T cell expansion. The PBMC will be activated with OKT3 and expanded in IL-2 to generate from 20-320 ×109 ATC during a maximum of 14 days of culture. Three patients will be treated at each dose level. The dose levels for each infusion are: 5, 10, 20, and 40 billion. Each patient will receive a total of 8 doses of armed ATC given twice weekly for 4 weeks. If the patients encounter toxicities related to armed ATC, the dose and administration will be modified as delineated per the protocol. The patients will also receive subcutaneous injections of IL-2 (3.0 × 105 IU/m2/day) starting 3 days before the 1st armed ATC infusion and ending 7 days after the last armed ATC infusion. GM-CSF (250μg/m2 twice per week) will given subcutaneously to start 3 days before the 1st armed ATC infusion and ending 7 days after the last dose of armed ATC.
|
Biological: Aldesleukin
Subcutaneous injections of IL-2 (3.0 × 105 IU/m2/day) starting 3 days before the 1st armed ATC infusion and ending 7 days after the last armed ATC infusion.
Other Names:
Biological: Sargramostim GM-CSF Injections will be given SQ GM-CSF (250 μg/m2/twice weekly), to start 3 days before the first ATC infusion and ending 1 week after the last ATC infusion.
Other Names:
Biological: therapeutic autologous lymphocytes The time for armed-ATC infusions will vary from patient to patient, but the dose of armed-ATC (up to 40 billion) will be given over 30 min. |
- Maximum tolerated dose [ Time Frame: The dose at which dose-limiting toxicity occurs is defined as that dose at which 2 or more of 6 patients at that dose level have their infusions stopped due to toxicities or receive less than 80% of the planned dose. ]
- Toxicity profile [ Time Frame: Months 1, 2, 5 and 11, then every 6 months ]
- Clinical responses [ Time Frame: Months: 1, 2, 5 and 11, then every 6 months ]
- Overall survival and progression-free survival [ Time Frame: The interval from the beginning of immunotherapy to the time of death or for progression free survival it is defined as the interval from the beginning of immunotherapy to progression ]
- Immune changes [ Time Frame: 1 (+ 7 days), 2 (+ 7 days), 5 months (+ 7 days), then every 6months (+ 7 days) (immune evaluations will also be performed after the 4th and 8th infusion of Her2Bi armed ATC and within 1week of the completion of HER2Bi armed ATC) ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 120 Years (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Phase I:
- Histologically confirmed infiltrating ductal carcinoma of the breast
-
Metastatic disease
- Clinically asymptomatic with non-life-threatening metastases allowed
-
Measurable or evaluable disease by radiograph, CT scan, MRI, nuclear medicine bone scan, or physical examination
- No measurable disease allowed if tumor or metastasis has been removed or successfully treated prior to study
- No rapidly progressive symptomatic disease affecting major organ systems (e.g., lungs and liver)
- Stable or unstable disease for 3 months on hormonal therapy
- Stable or unstable disease for at least 1 month after chemotherapy
-
No active brain metastases
- Brain metastases previously treated with definitive radiotherapy and/or surgical resection allowed
-
Hormone receptor status:
- Estrogen and progesterone receptor status known
Phase II:
- All Phase I criteria
-
HER2/neu overexpression (2+ or 3+) by immunohistochemistry
- Prior trastuzumab (Herceptin) allowed if disease still overexpresses HER2/neu
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Sex:
- Female
Menopausal status:
- Not specified
Performance status:
- Karnofsky 70-100% OR
- ECOG 0-2
Life expectancy:
- At least 3 months
Hematopoietic:
- Granulocyte count at least 1,500/mm^3
- Platelet count at least 50,000/mm^3
- Hemoglobin at least 8 g/dL
Hepatic:
- Bilirubin less than 1.5 times normal
- SGOT less than 1.5 times normal
Renal:
- Creatinine no greater than 1.8 mg/dL
- Creatinine clearance at least 60 mL/min
- BUN no greater than 1.5 times normal
Cardiovascular:
- No myocardial infarction within the past year
- No prior myocardial infarction with coronary symptoms requiring medication and/or depressed left ventricular function (LVEF less than 50% by MUGA)
- No angina or coronary symptoms requiring medication and/or with depressed left ventricular function (LVEF less than 50% by MUGA)
- No congestive heart failure requiring medical management
- LVEF at least 50% at rest by MUGA
- No uncontrolled hypertension (i.e., systolic blood pressure [BP] ≥ 130 mm Hg or diastolic BP ≥ 80 mm Hg)
Pulmonary:
- FEV1, DLCO, and FVC at least 50% predicted
Other:
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- HIV negative
- No other serious medical or psychiatric illness that would preclude study participation
- No other prior or concurrent malignancy within the past 5 years except curatively treated squamous cell carcinoma in situ of the cervix, basal cell skin cancer, or any other curatively treated disease in complete remission
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- See Disease Characteristics
- Prior trastuzumab allowed for phase I
Chemotherapy:
- See Disease Characteristics
- At least 4 weeks since prior chemotherapy
Endocrine therapy:
- See Disease Characteristics
- Concurrent hormonal therapy for breast cancer must continue during study
- No other concurrent hormonal therapy except steroids for adrenal failure, septic shock, or pulmonary toxicity or hormonal therapy for non-disease-related conditions (e.g., insulin for diabetes)
Radiotherapy:
- See Disease Characteristics
Surgery:
- See Disease Characteristics

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00027807
United States, Michigan | |
Barbara Ann Karmanos Cancer Institute | |
Detroit, Michigan, United States, 48201-1379 |
Study Chair: | Lawrence G. Lum, MD, DSc | Barbara Ann Karmanos Cancer Institute |
Other Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Lawrence Lum, Principal Investigator, Barbara Ann Karmanos Cancer Institute |
ClinicalTrials.gov Identifier: | NCT00027807 |
Other Study ID Numbers: |
CDR0000069072 P30CA022453 ( U.S. NIH Grant/Contract ) 2006-130 ( Other Identifier: Karmanos Cancer Institute ) RWMC-0635146 WSU-010307M1F ( Other Identifier: Wayne State University - Human Investigation Committee ) WSU-0312004412 ( Other Identifier: Wayne State University - Human Investigation Committee ) |
First Posted: | January 27, 2003 Key Record Dates |
Last Update Posted: | February 17, 2016 |
Last Verified: | February 2016 |
stage IV breast cancer recurrent breast cancer ductal breast carcinoma |
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Aldesleukin Molgramostim Sargramostim |
Immunologic Factors Physiological Effects of Drugs Antineoplastic Agents Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents |